Amalgamated Bank Sells 5,880 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Amalgamated Bank cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,286 shares of the medical equipment provider’s stock after selling 5,880 shares during the period. Amalgamated Bank’s holdings in Zimmer Biomet were worth $6,120,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. PFG Advisors increased its position in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after purchasing an additional 84 shares during the period. Quent Capital LLC boosted its position in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in shares of Zimmer Biomet by 5.0% during the third quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after purchasing an additional 97 shares during the period. Financial Advocates Investment Management increased its holdings in Zimmer Biomet by 3.8% in the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 97 shares during the last quarter. Finally, Stokes Family Office LLC boosted its holdings in Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 99 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 2.7 %

Zimmer Biomet stock opened at $121.66 on Monday. The stock has a market cap of $25.03 billion, a P/E ratio of 26.33, a P/E/G ratio of 2.23 and a beta of 1.03. The company’s 50-day moving average price is $125.30 and its two-hundred day moving average price is $120.21. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $147.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.89 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Insider Activity

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. StockNews.com lowered shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 23rd. Barclays boosted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $135.40.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.